Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrations

Referencias bibliográficas

• Aihara, K. et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. 1003, 9–17 (2004).
• Argo, T. R., Carnahan, R. M. & Perry, P. J. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 24, 212–228 (2004).
• Toja-Camba, F. J. et al. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics. Pharmaceutics 13, 935 (2021).
• Hiemke, C. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51, 9–62 (2018).
• Juliano, R. L. & Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152–162 (1976).
• Liu, X. ABC family transporters. Adv. Exp. Med. Biol. 1141, 13–100 (2019).
• Taskar, K. S. et al. Clinical relevance of hepatic and renal P-gp/BCRP inhibition of drugs: An international transporter consortium perspective. Clin. Pharmacol. Ther. 112, 573–592 (2022).
• Riordan, J. R. et al. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316, 817–819 (1985).
• Yoo, H.-D. et al. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br. J. Pharmacol. 164, 433–443 (2011).
• Kimchi-Sarfaty, C. et al. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 8, 29–39 (2007).
• Gurney, H. et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin. Pharmacol. Ther. 82, 33–40 (2007).
• Miyata, K., Nakagawa, Y., Kimura, Y., Ueda, K. & Akamatsu, M. In vitro and in vivo evaluations of the P-glycoprotein-mediated efflux of dibenzoylhydrazines. Toxicol. Appl. Pharmacol. 298, 40–47 (2016).
• Sharom, F. J. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9, 105–127 (2008).
• Tang, K., Wong, L. P., Lee, E. J. D., Chong, S. S. & Lee, C. G. L. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum. Mol. Genet. 13, 783–797 (2004).
• Belmonte, C. et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 122, 596–605 (2018).
• Moons, T., De Roo, M., Claes, S. & Dom, G. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12, 1193–1211 (2011).
• Simon, C. et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol. Scand. 115, 232–242 (2007).
• Kim, S. W. et al. Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR. Cell. Signal. 31, 124–134 (2017).
• Lopes-Rodrigues, V. et al. Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells. Biochim. Biophys. Acta BBA Gen. Subj. 1860, 618–627 (2016).
• Table of Substrates, Inhibitors and Inducers, FDA, F. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers. FDA (2024).
• Hoffmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97, 3473–3478 (2000).
• Kirschbaum, K. M. et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 59, 474–479 (2010).
• Toja-Camba, F. J. et al. Towards precision medicine in clinical practice: Alinity C vs. UHPLC-MS/MS in plasma aripiprazole determination. Pharmaceutics 16, 104 (2024).
• Caudle, K. E. et al. Standardizing CYP 2D6 genotype to phenotype translation: Consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin. Transl. Sci. 13, 116–124 (2020).
• Bernal, M. L., Sinues, B., Fanlo, A. & Mayayo, E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther. Drug Monit. 25, 107 (2003).
• Kroetz, D. L. et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13, 481–494 (2003).
• Suzuki, T. et al. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther. Drug Monit. 36, 651–655 (2014).
• Rafaniello, C. et al. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogen. J. 18, 422–430 (2018).
• SmPC Abilify Maintena, Otsuka Pharmaceuticals. ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension, for intramuscular use [package insert]. Tokyo (Japan): Otsuka Pharmaceuticals Co. Ltd.; 2015. Revised: Dec/2020 (2024).
• Wang, J.-S. et al. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr. Res. 110, 90–94 (2009).
• Wolking, S., Schaeffeler, E., Lerche, H., Schwab, M. & Nies, A. T. Impact of Genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: Update of the literature. Clin. Pharmacokinet. 54, 709–735 (2015).